Antiviral and apoptosis modulating effect of methylenebisphosphonic acids

  • Naumenko K
  • Zagorodnya S
  • Golovan A
  • Kovtyn V
Keywords: Epstein-Barr virus, apoptosis, methylenebisphosphonic acids

Abstract

The research of the molecular and genetic characteristics of Epstein-Barr virus are going for years and its ability to develop lymphoproliferative diseases. However, the search for effective antiviral and anticancer drugs remains relevant today. The aim was to investigate the biological properties methylenebisphosphonic acids (10s20-22), including cytotoxicity, apoptosis stimulating and antiviral activity. For this we used MTT-metod, PCR and flow cytometry. Also bioinformatic analysis was conducted using compounds PASS. It was shown 10s-20 compound effectively inhibits the replication of EBV in low concentrations. Compound 10c-21 showed a significant effect on apoptosis stimulating B95-8 cells. Data analysis showed prediction that this class of compounds may be a substrate for cytochrome C (CYP2H), which in turn may indicate the involvement of mitochondrial ways of inducing apoptosis. The data indicate that the group methylenebisphosphonic acids are perspective for further research

Downloads

Download data is not yet available.

Author Biographies

Naumenko K

Zabolotny Institute of Microbiology and Virology NAN Ukraine

154 Acad. Zabolotny str
Zagorodnya S

Zabolotny Institute of Microbiology and Virology NAN Ukraine

154 Acad. Zabolotny str
Golovan A

Zabolotny Institute of Microbiology and Virology NAN Ukraine

154 Acad. Zabolotny str
Kovtyn V

Taras Shevchenko National University of Kyiv

2 Acad. Glushkov avenue, Kiev

References

I. Chi Young Ok, Ling Li, Ken H Young, EBV-driven B-cell limphoproliferative disorders: from biology, cladfication and differential diagnosis to clinical management // Experimental and Molecular Medicine. – 2015
II. EBV-asociated cancers: Strategies for targeting the virus, R. T. Lima, M. S. J. Nascimento, M. H. Vasconcelos, Microbal pathogens and strategies for combating them: science, technology and education, 2013, 1608-1618
III. Myung-Soo Kang1,2 and Elliott Kieff, Epstein–Barr virus latent genes, Experimental & Molecular Medicine (2015) 47, 1-16
IV. Young-Hyer Ko, EBV and human cancer, Experimental & Molecular Medicine, 2015, 47, 1-3
V. Epstein-Barr virus-associated B-cell lymphomas: pathogenesis and clinical outcomes, A. Saha, E. Robertson, Clin cancer res, 17, 10, 2011, 3056-3063
VI. Jung-Chung Lin. Antiviral therapy for Epstein-Barr virus-associated diseases // Tzu Chi Med. J. – 2005. – 17, N1. – p. 379-385
VII. Anette Holck Draborg, Karen Duus, and Gunnar Houen Epstein-Barr Virus in Systemic Autoimmune Diseases // Clin Dev Immunol. – 2013. – Vol. 2013. – p. 1-9
VIII. In silico drug design-tool for overcoming the innovation deficit in the drug discovery process, E. N. Bharath, S. N. Manjula, A. Vijaychand, Int J Pharm Sci vol3, issue2, 2011, 8-12
IX. R. Berthelsen, E. Sjӧgren, J. Jacobsen, J. Kristensen, R. Holm, B. Abrahamsson, A. Müllertz, Combining in vitro and in silico methods for better prediction of surfactant effects on the absorption of poorly water soluble drugs – a fenofibrate case example, International Journal of Pharmaceutics, 473, 2014, 356-365
X. S.V.Zasukha, A.I. Gudz, G.P. Gudz, Yu.G. Shermolovich, Synthesis of bisphosohonate analogs of nucleotides – derivatives of (α-phenyl)(α-fluoro)methylenebisphosphonic acids, Journal of Organic and Pharmaceutical Chemistry. 2014. – Vol.12, N.4. – p. 55-64.
XI. Alet van Tonder, Annie M Joubert, A Duncan Cromarty, Limitations of the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay when compared to three commonly used cell enumeration assays, BMC Research Notes (2015), 8,47
XII. C. A Romain, H. H Balfour Jr, H. E Vezina, C. J Holman, A method for evaluating antiviral drug susceptibility of Epstein-Barr virus. 2010. 2:1-7
XIII. Analysis of apoptosis by propidium iodide staining and flow cytometry, C. Riccardi, I. Nicoletti, Natue protocols, 2006, vol.1N3, 1458-1461
XIV. Lagunin A., StepanchikovaA., Filimonov D. PASS: prediction of activity spectra for biologically active substances // Bioinformatics. – 2000. – Vol.8, N8. – p. 747-748,
XV. Prediction of biological activity spectra for few anticancer drugs derived from plant sources. A. John De Britto, T. Leon Stephan Raj, D. Abiya Chelliah, Ethobotanical leaflets 12:801-10, 2001,
XVI. P. G. Jamkhade, A. S. Wattamwar, S. S. Pekamwar, P. G. Chandar, Antioxidant, antimicrobial activity and in silico PASS prediction of Annona reticulate Linn. Root extract, Journal of basic and applied sciences, 2014, 3, 140-148
XVII. Lapach S.N., Chubenco A.V., Babich P.N. Statistical methods in medical and biological research using Excel.- К.: МОRIОN. - 2001. – 408 p.
XVIII. Virally targeted therapies for EBV-associated magnignancies, B. F Israel, S. C Kenney, oncogene, 2003, 22, 5122-5130
XIX. Chi Young Ok, Ling Li, Ken H Young, EBV-driven B-cell limphoproliferative disorders: from biology, cladfication and differential diagnosis to clinical management // Experimental and Molecular Medicine. – 2015
XX. hTERT Ingibition triggers Epstein-Barr virus lytic cycle and apoptosis in immortalized and transformed B cell: a basis for new therapies, S. Giunco, R. Dolcetti, S. Keppel, A. Celeghin, S. Indraccolo, J. Dal Col, K. Mastorci, A. De Rossi. Clin Cancer Res. 2013. 1-12
XXI. Effects of n-Butyrate and phorbol ester (TPA) on induction of Epstein-Barr virus antigens and cell differentiation, E. Anisimova, K. Prachova, J. Roubal, V. Vonka, Archives of virology 81, 223-237, 1984
XXII. Efficient synthesis of fluorothiosparfosic acid analogues with potential antitumoral activity, E. Pfund, T. Lequeux, S. Masson, M. Vazeux, A. Cordi, A. Pierre, V. Serre, G. Herve, Bioorganic and medical chemistry 13, 2005, 4921-4928
XXIII. Fluorinated nucleosides: synthesis and biological implication, Peng Liu, Ashoke Sharon, Chung K. Chu, J Fluor Chem. 2008, 129(9), 743-766
Published
2016-08-16
Section
Articles